[
  {
    "ts": null,
    "headline": "Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025",
    "summary": "FOSTER CITY, Calif., July 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2025 financial results and guidance will be released on Thursday, August 7, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2025 financial results and provide a business update.",
    "url": "https://finnhub.io/api/news?id=9e37a5e8a574d10d4f3259a7ab8793621337620162654d3398a04b2514230f21",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753387500,
      "headline": "Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025",
      "id": 136085104,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., July 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2025 financial results and guidance will be released on Thursday, August 7, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2025 financial results and provide a business update.",
      "url": "https://finnhub.io/api/news?id=9e37a5e8a574d10d4f3259a7ab8793621337620162654d3398a04b2514230f21"
    }
  },
  {
    "ts": null,
    "headline": "CAR T-Cell Therapy Market Trends and Forecasts, 2021-2024 & 2025-2033 | Focus on Yescarta, Tecartus, Kymriah, Breyanzi, Abecma, Carvykti, and Carteyva",
    "summary": "The global CAR T-cell therapy market is set to expand from USD 4.6 billion in 2024 to USD 18.1 billion by 2033, driven by rising cancer cases and demand for personalized medicine. Key players like Novartis and Gilead Sciences lead in innovation. Market growth is fueled by ongoing clinical trials and investments.Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The \"CAR T-Cell Therapy Market Size, Growth, Share, Trends and Forecasts 2025-2033\" report has been added to ResearchAndMarkets.com's offering. T",
    "url": "https://finnhub.io/api/news?id=fa6d0f3e6760b17ef9fffd2572bae59b757cfce716d547f4b83862b6bb959685",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753345200,
      "headline": "CAR T-Cell Therapy Market Trends and Forecasts, 2021-2024 & 2025-2033 | Focus on Yescarta, Tecartus, Kymriah, Breyanzi, Abecma, Carvykti, and Carteyva",
      "id": 136066484,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The global CAR T-cell therapy market is set to expand from USD 4.6 billion in 2024 to USD 18.1 billion by 2033, driven by rising cancer cases and demand for personalized medicine. Key players like Novartis and Gilead Sciences lead in innovation. Market growth is fueled by ongoing clinical trials and investments.Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The \"CAR T-Cell Therapy Market Size, Growth, Share, Trends and Forecasts 2025-2033\" report has been added to ResearchAndMarkets.com's offering. T",
      "url": "https://finnhub.io/api/news?id=fa6d0f3e6760b17ef9fffd2572bae59b757cfce716d547f4b83862b6bb959685"
    }
  }
]